APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Human Microbiome

The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.

An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

Selected research

Market Outlook & Growth Opportunities

Global Human Microbiome Market Outlook and Growth Opportunities 2026

Report ID 173894440423 December 2025207 pages

Choose your research edition.

Industry ResearchHuman Microbiome Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Microbiome Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Human Microbiome Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Microbiome Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Microbiome Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.

An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

Read the full market overview

At present, global investment concentrates in US and Europe, US takes 70% market share and Europe takes 25% market share. There are a few manufacturers in the world and the market concentration is high. The top5 (investment in Human Micobiome) companies are Vedanta, Seres Therapeutics, Second Genome, Rebiocix, ActoGeniX. The five companies occupy about 70% of the market share.

This report provides an overview of the global Human Microbiome market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Microbiome and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Microbiome revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Human Microbiome market.

Human Microbiome Segment by Company

Vedanta

Seres Therapeutics

Second Genome

Rebiotix

ActoGeniX

Enterome BioScience

AvidBiotics

4D Pharma Research Ltd

Enterologics

Metabogen

Metabiomics

Ritter Pharmaceuticals

Osel

Symberix

Miomics

Symbiotix Biotherapies

MicroBiome Therapeutics LLC

Human Microbiome Segment by Type

Gastrointestinal Tract Human Micobiome

Urogenital Tract Human Micobiome

Others

Human Microbiome Segment by Application

Treatment

Diagnosis

Human Microbiome Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Human Microbiome status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Human Microbiome key companies, revenue, market share, and recent developments.

3. To split the Human Microbiome breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Human Microbiome market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Microbiome significant trends, drivers, influence factors in global and regions.

6. To analyze Human Microbiome competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Microbiome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Microbiome and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Microbiome.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Microbiome industry.

Chapter 3: Detailed analysis of Human Microbiome company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Human Microbiome in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Human Microbiome in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Microbiome Industry Trends Table 2. Human Microbiome Industry Drivers Table 3. Human Microbiome Industry Opportunities and Challenges Table 4. Human Microbiome Industry Restraints Table 5. Global Human Microbiome Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Microbiome Revenue Share by Company (2021-2026) Table 7. Global Human Microbiome Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Human Microbiome Key Company Manufacturing Base & Headquarters Table 9. Global Human Microbiome Company, Product Type & Application Table 10. Global Human Microbiome Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Human Microbiome by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Gastrointestinal Tract Human Micobiome Table 15. Significant Companies of Urogenital Tract Human Micobiome Table 16. Significant Companies of Others Table 17. Global Human Microbiome Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Human Microbiome Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Human Microbiome Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Human Microbiome Sales Value Share by Type (2021-2026) Table 21. Global Human Microbiome Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Treatment Table 23. Significant Companies of Diagnosis Table 24. Global Human Microbiome Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Human Microbiome Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Human Microbiome Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Human Microbiome Sales Value Share by Application (2021-2026) Table 28. Global Human Microbiome Sales Value Share by Application (2027-2032) Table 29. Global Human Microbiome Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Human Microbiome Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Human Microbiome Sales Value Share by Region (2021-2026) Table 32. Global Human Microbiome Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Human Microbiome Sales Value Share by Region (2027-2032) Table 34. Global Human Microbiome Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Human Microbiome Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Human Microbiome Sales Value Market Share by Country (2021-2026) Table 37. Global Human Microbiome Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Human Microbiome Sales Value Market Share by Country (2027-2032) Table 39. Vedanta Company Information Table 40. Vedanta Business Overview Table 41. Vedanta Human Microbiome Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Vedanta Human Microbiome Product Portfolio Table 43. Vedanta Recent Development Table 44. Seres Therapeutics Company Information Table 45. Seres Therapeutics Business Overview Table 46. Seres Therapeutics Human Microbiome Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Seres Therapeutics Human Microbiome Product Portfolio Table 48. Seres Therapeutics Recent Development Table 49. Second Genome Company Information Table 50. Second Genome Business Overview Table 51. Second Genome Human Microbiome Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Second Genome Human Microbiome Product Portfolio Table 53. Second Genome Recent Development Table 54. Rebiotix Company Information Table 55. Rebiotix Business Overview Table 56. Rebiotix Human Microbiome Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Rebiotix Human Microbiome Product Portfolio Table 58. Rebiotix Recent Development Table 59. ActoGeniX Company Information Table 60. ActoGeniX Business Overview Table 61. ActoGeniX Human Microbiome Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. ActoGeniX Human Microbiome Product Portfolio Table 63. ActoGeniX Recent Development Table 64. Enterome BioScience Company Information Table 65. Enterome BioScience Business Overview Table 66. Enterome BioScience Human Microbiome Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Enterome BioScience Human Microbiome Product Portfolio Table 68. Enterome BioScience Recent Development Table 69. AvidBiotics Company Information Table 70. AvidBiotics Business Overview Table 71. AvidBiotics Human Microbiome Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. AvidBiotics Human Microbiome Product Portfolio Table 73. AvidBiotics Recent Development Table 74. 4D Pharma Research Ltd Company Information Table 75. 4D Pharma Research Ltd Business Overview Table 76. 4D Pharma Research Ltd Human Microbiome Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. 4D Pharma Research Ltd Human Microbiome Product Portfolio Table 78. 4D Pharma Research Ltd Recent Development Table 79. Enterologics Company Information Table 80. Enterologics Business Overview Table 81. Enterologics Human Microbiome Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Enterologics Human Microbiome Product Portfolio Table 83. Enterologics Recent Development Table 84. Metabogen Company Information Table 85. Metabogen Business Overview Table 86. Metabogen Human Microbiome Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Metabogen Human Microbiome Product Portfolio Table 88. Metabogen Recent Development Table 89. Metabiomics Company Information Table 90. Metabiomics Business Overview Table 91. Metabiomics Human Microbiome Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 92. Metabiomics Human Microbiome Product Portfolio Table 93. Metabiomics Recent Development Table 94. Ritter Pharmaceuticals Company Information Table 95. Ritter Pharmaceuticals Business Overview Table 96. Ritter Pharmaceuticals Human Microbiome Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 97. Ritter Pharmaceuticals Human Microbiome Product Portfolio Table 98. Ritter Pharmaceuticals Recent Development Table 99. Osel Company Information Table 100. Osel Business Overview Table 101. Osel Human Microbiome Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 102. Osel Human Microbiome Product Portfolio Table 103. Osel Recent Development Table 104. Symberix Company Information Table 105. Symberix Business Overview Table 106. Symberix Human Microbiome Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 107. Symberix Human Microbiome Product Portfolio Table 108. Symberix Recent Development Table 109. Miomics Company Information Table 110. Miomics Business Overview Table 111. Miomics Human Microbiome Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 112. Miomics Human Microbiome Product Portfolio Table 113. Miomics Recent Development Table 114. Symbiotix Biotherapies Company Information Table 115. Symbiotix Biotherapies Business Overview Table 116. Symbiotix Biotherapies Human Microbiome Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 117. Symbiotix Biotherapies Human Microbiome Product Portfolio Table 118. Symbiotix Biotherapies Recent Development Table 119. MicroBiome Therapeutics LLC Company Information Table 120. MicroBiome Therapeutics LLC Business Overview Table 121. MicroBiome Therapeutics LLC Human Microbiome Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 122. MicroBiome Therapeutics LLC Human Microbiome Product Portfolio Table 123. MicroBiome Therapeutics LLC Recent Development Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Human Microbiome Product Image Figure 2. Global Human Microbiome Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Microbiome Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Microbiome Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Gastrointestinal Tract Human Micobiome Image Figure 8. Urogenital Tract Human Micobiome Image Figure 9. Others Image Figure 10. Global Human Microbiome Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Human Microbiome Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Human Microbiome Sales Value Share by Type (2021-2032) Figure 13. Treatment Image Figure 14. Diagnosis Image Figure 15. Global Human Microbiome Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Human Microbiome Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Human Microbiome Sales Value Share by Application (2021-2032) Figure 18. Global Human Microbiome Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Human Microbiome Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Human Microbiome Sales Value (2021-2032) & (US$ Million) Figure 21. North America Human Microbiome Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Human Microbiome Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Human Microbiome Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Human Microbiome Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Human Microbiome Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Human Microbiome Sales Value (2021-2032) & (US$ Million) Figure 27. South America Human Microbiome Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Human Microbiome Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Human Microbiome Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Human Microbiome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Human Microbiome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Human Microbiome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Gastrointestinal Tract Human Micobiome
  • Urogenital Tract Human Micobiome
  • Others
Applications
  • Treatment
  • Diagnosis
Companies covered
  • Vedanta
  • Seres Therapeutics
  • Second Genome
  • Rebiotix
  • ActoGeniX
  • Enterome BioScience
  • AvidBiotics
  • 4D Pharma Research Ltd
  • Enterologics
  • Metabogen
  • Metabiomics
  • Ritter Pharmaceuticals
  • Osel
  • Symberix
  • Miomics
  • Symbiotix Biotherapies
  • MicroBiome Therapeutics LLC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Microbiome Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Microbiome Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Human Microbiome Market Dynamics
  1. 2.1 Human Microbiome Industry Trends
  2. 2.2 Human Microbiome Industry Drivers
  3. 2.3 Human Microbiome Industry Opportunities and Challenges
  4. 2.4 Human Microbiome Industry Restraints
3 Human Microbiome Market by Company
  1. 3.1 Global Human Microbiome Company Revenue Ranking in 2025
  2. 3.2 Global Human Microbiome Revenue by Company (2021-2026)
  3. 3.3 Global Human Microbiome Company Ranking (2024-2026)
  4. 3.4 Global Human Microbiome Company Manufacturing Base and Headquarters
  5. 3.5 Global Human Microbiome Company Product Type and Application
  6. 3.6 Global Human Microbiome Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Human Microbiome Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Human Microbiome Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Human Microbiome Market by Type
  1. 4.1 Human Microbiome Type Introduction
  2. 4.1.1 Gastrointestinal Tract Human Micobiome
  3. 4.1.2 Urogenital Tract Human Micobiome
  4. 4.1.3 Others
  5. 4.2 Global Human Microbiome Sales Value by Type
  6. 4.2.1 Global Human Microbiome Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Human Microbiome Sales Value by Type (2021-2032)
  8. 4.2.3 Global Human Microbiome Sales Value Share by Type (2021-2032)
5 Human Microbiome Market by Application
  1. 5.1 Human Microbiome Application Introduction
  2. 5.1.1 Treatment
  3. 5.1.2 Diagnosis
  4. 5.2 Global Human Microbiome Sales Value by Application
  5. 5.2.1 Global Human Microbiome Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Human Microbiome Sales Value by Application (2021-2032)
  7. 5.2.3 Global Human Microbiome Sales Value Share by Application (2021-2032)
6 Human Microbiome Regional Value Analysis
  1. 6.1 Global Human Microbiome Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Microbiome Sales Value by Region (2021-2032)
  3. 6.2.1 Global Human Microbiome Sales Value by Region: 2021-2026
  4. 6.2.2 Global Human Microbiome Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Microbiome Sales Value (2021-2032)
  7. 6.3.2 North America Human Microbiome Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Human Microbiome Sales Value (2021-2032)
  10. 6.4.2 Europe Human Microbiome Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Human Microbiome Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Human Microbiome Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Human Microbiome Sales Value (2021-2032)
  16. 6.6.2 South America Human Microbiome Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Human Microbiome Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Human Microbiome Sales Value Share by Country, 2025 VS 2032
7 Human Microbiome Country-level Value Analysis
  1. 7.1 Global Human Microbiome Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Microbiome Sales Value by Country (2021-2032)
  3. 7.2.1 Global Human Microbiome Sales Value by Country (2021-2026)
  4. 7.2.2 Global Human Microbiome Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Human Microbiome Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Human Microbiome Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Human Microbiome Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Human Microbiome Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Human Microbiome Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Human Microbiome Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Human Microbiome Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Human Microbiome Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Human Microbiome Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Human Microbiome Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Human Microbiome Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Human Microbiome Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Human Microbiome Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Human Microbiome Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Human Microbiome Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Human Microbiome Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Human Microbiome Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Human Microbiome Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Human Microbiome Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Human Microbiome Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Human Microbiome Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Human Microbiome Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Human Microbiome Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Human Microbiome Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Human Microbiome Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Human Microbiome Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Human Microbiome Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Human Microbiome Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Human Microbiome Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Human Microbiome Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Human Microbiome Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Human Microbiome Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Human Microbiome Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Human Microbiome Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Human Microbiome Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Human Microbiome Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Human Microbiome Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Human Microbiome Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Human Microbiome Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Human Microbiome Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Human Microbiome Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Human Microbiome Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Human Microbiome Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Human Microbiome Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Human Microbiome Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Human Microbiome Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Human Microbiome Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Human Microbiome Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Human Microbiome Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Human Microbiome Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Human Microbiome Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Human Microbiome Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Human Microbiome Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Human Microbiome Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Human Microbiome Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Human Microbiome Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Human Microbiome Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Human Microbiome Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Human Microbiome Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Human Microbiome Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Human Microbiome Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Human Microbiome Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Human Microbiome Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Human Microbiome Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Human Microbiome Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Human Microbiome Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Human Microbiome Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Human Microbiome Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Human Microbiome Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Human Microbiome Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Human Microbiome Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Human Microbiome Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Human Microbiome Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Human Microbiome Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Human Microbiome Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Human Microbiome Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Human Microbiome Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Human Microbiome Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Human Microbiome Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Human Microbiome Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Human Microbiome Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Human Microbiome Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Human Microbiome Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Human Microbiome Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Vedanta
  2. 8.1.1 Vedanta Company Information
  3. 8.1.2 Vedanta Business Overview
  4. 8.1.3 Vedanta Human Microbiome Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Vedanta Human Microbiome Product Portfolio
  6. 8.1.5 Vedanta Recent Developments
  7. 8.2 Seres Therapeutics
  8. 8.2.1 Seres Therapeutics Company Information
  9. 8.2.2 Seres Therapeutics Business Overview
  10. 8.2.3 Seres Therapeutics Human Microbiome Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Seres Therapeutics Human Microbiome Product Portfolio
  12. 8.2.5 Seres Therapeutics Recent Developments
  13. 8.3 Second Genome
  14. 8.3.1 Second Genome Company Information
  15. 8.3.2 Second Genome Business Overview
  16. 8.3.3 Second Genome Human Microbiome Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Second Genome Human Microbiome Product Portfolio
  18. 8.3.5 Second Genome Recent Developments
  19. 8.4 Rebiotix
  20. 8.4.1 Rebiotix Company Information
  21. 8.4.2 Rebiotix Business Overview
  22. 8.4.3 Rebiotix Human Microbiome Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Rebiotix Human Microbiome Product Portfolio
  24. 8.4.5 Rebiotix Recent Developments
  25. 8.5 ActoGeniX
  26. 8.5.1 ActoGeniX Company Information
  27. 8.5.2 ActoGeniX Business Overview
  28. 8.5.3 ActoGeniX Human Microbiome Revenue and Gross Margin (2021-2026)
  29. 8.5.4 ActoGeniX Human Microbiome Product Portfolio
  30. 8.5.5 ActoGeniX Recent Developments
  31. 8.6 Enterome BioScience
  32. 8.6.1 Enterome BioScience Company Information
  33. 8.6.2 Enterome BioScience Business Overview
  34. 8.6.3 Enterome BioScience Human Microbiome Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Enterome BioScience Human Microbiome Product Portfolio
  36. 8.6.5 Enterome BioScience Recent Developments
  37. 8.7 AvidBiotics
  38. 8.7.1 AvidBiotics Company Information
  39. 8.7.2 AvidBiotics Business Overview
  40. 8.7.3 AvidBiotics Human Microbiome Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AvidBiotics Human Microbiome Product Portfolio
  42. 8.7.5 AvidBiotics Recent Developments
  43. 8.8 4D Pharma Research Ltd
  44. 8.8.1 4D Pharma Research Ltd Company Information
  45. 8.8.2 4D Pharma Research Ltd Business Overview
  46. 8.8.3 4D Pharma Research Ltd Human Microbiome Revenue and Gross Margin (2021-2026)
  47. 8.8.4 4D Pharma Research Ltd Human Microbiome Product Portfolio
  48. 8.8.5 4D Pharma Research Ltd Recent Developments
  49. 8.9 Enterologics
  50. 8.9.1 Enterologics Company Information
  51. 8.9.2 Enterologics Business Overview
  52. 8.9.3 Enterologics Human Microbiome Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Enterologics Human Microbiome Product Portfolio
  54. 8.9.5 Enterologics Recent Developments
  55. 8.10 Metabogen
  56. 8.10.1 Metabogen Company Information
  57. 8.10.2 Metabogen Business Overview
  58. 8.10.3 Metabogen Human Microbiome Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Metabogen Human Microbiome Product Portfolio
  60. 8.10.5 Metabogen Recent Developments
  61. 8.11 Metabiomics
  62. 8.11.1 Metabiomics Company Information
  63. 8.11.2 Metabiomics Business Overview
  64. 8.11.3 Metabiomics Human Microbiome Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Metabiomics Human Microbiome Product Portfolio
  66. 8.11.5 Metabiomics Recent Developments
  67. 8.12 Ritter Pharmaceuticals
  68. 8.12.1 Ritter Pharmaceuticals Company Information
  69. 8.12.2 Ritter Pharmaceuticals Business Overview
  70. 8.12.3 Ritter Pharmaceuticals Human Microbiome Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Ritter Pharmaceuticals Human Microbiome Product Portfolio
  72. 8.12.5 Ritter Pharmaceuticals Recent Developments
  73. 8.13 Osel
  74. 8.13.1 Osel Company Information
  75. 8.13.2 Osel Business Overview
  76. 8.13.3 Osel Human Microbiome Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Osel Human Microbiome Product Portfolio
  78. 8.13.5 Osel Recent Developments
  79. 8.14 Symberix
  80. 8.14.1 Symberix Company Information
  81. 8.14.2 Symberix Business Overview
  82. 8.14.3 Symberix Human Microbiome Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Symberix Human Microbiome Product Portfolio
  84. 8.14.5 Symberix Recent Developments
  85. 8.15 Miomics
  86. 8.15.1 Miomics Company Information
  87. 8.15.2 Miomics Business Overview
  88. 8.15.3 Miomics Human Microbiome Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Miomics Human Microbiome Product Portfolio
  90. 8.15.5 Miomics Recent Developments
  91. 8.16 Symbiotix Biotherapies
  92. 8.16.1 Symbiotix Biotherapies Company Information
  93. 8.16.2 Symbiotix Biotherapies Business Overview
  94. 8.16.3 Symbiotix Biotherapies Human Microbiome Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Symbiotix Biotherapies Human Microbiome Product Portfolio
  96. 8.16.5 Symbiotix Biotherapies Recent Developments
  97. 8.17 MicroBiome Therapeutics LLC
  98. 8.17.1 MicroBiome Therapeutics LLC Company Information
  99. 8.17.2 MicroBiome Therapeutics LLC Business Overview
  100. 8.17.3 MicroBiome Therapeutics LLC Human Microbiome Revenue and Gross Margin (2021-2026)
  101. 8.17.4 MicroBiome Therapeutics LLC Human Microbiome Product Portfolio
  102. 8.17.5 MicroBiome Therapeutics LLC Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst